Managing Myeloma
- 2013-09-09 - Cancer Researchers Find Root Cause of Multiple Myeloma Relapse
- 2013-08-25 - Amgen to Buy Onyx Pharmaceuticals in $10.4B Deal; $125/share
- 2013-08-05 - IMF: NEWLY PUBLISHED STUDY SAYS PATIENTS IDENTIFIED WITH HIGH-RISK PRESYMPTOMATIC MYELOMA MAY BENEFIT FROM EARLY INTERVENTION - International Myeloma Foundation Press Release
- 2013-06-03 - ASCO: Prolonged Survival in Multiple Myeloma Predicted Using Deep Sequencing - CancerNetwork/Journal of Oncology
- 2013-06-03 - EMA backs Pomalidomide Celgene in multiple myeloma - PMLiVE
- 2013-06-03 - Celgene (CELG) Unit to Present Statistically Significant Data from MPR on Multiple Myeloma - StreetInsider
- 2013-06-03 - ASCO Presentation Highlights Results of Single Agent oral MLN9708 in Heavily Pretreated Patients with Relapsed and/or Refractory Multiple Myeloma - Fort Mill Times
- 2013-03-12 - Aeterna Zentaris to Discontinue Phase 3 Trial in Multiple Myeloma with Perifosine Following Data Safety Monitoring Board Recommendation
- 2013-02-18 - Stories your Patients May be Talking About: Targeted Cancer Drugs Keep Myeloma Patients Up And Running - NPR
- 2013-02-08 - NEWS FLASH...FDA approves Pomalidomide (Pomalyst) for advanced multiple myeloma
- 2013-01-23 - New Research May Aid Treatment in Multiple Myeloma Patients
- 2012-12-04 - The Multiple Myeloma Research Foundation (MMRF) and GenoSpace Partner to Launch Groundbreaking Information Ecosystem -- MMRF News Release
- 2012-10-03 - NextBio, Emory University partner to identify biomarkers and treatments for cancer patients -- Pharmabiz.com
- 2012-10-03 - Celgene Corporation Provides Update on FDA Advisory Committee for Pomalidomide -- DailyFinance
- 2012-10-02 - Janssen-Cilag receives authorization for multiple myeloma treatment in Europe